Wang Jian-Rong, Huang Jin-Yu, Hu Wei, Cai Xue-Ying, Hu Wei-Hang, Zhu Ying
Jian-rong Wang, MS. Department of Critical Care Medicine, The Affiliated Hangzhou Hospital of Nanjing Medical University, Zhejiang, China.
Jin-yu Huang, MD. Department of Cardiology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Zhejiang, China.
Pak J Med Sci. 2020 Sep-Oct;36(6):1171-1176. doi: 10.12669/pjms.36.6.2882.
We aimed to evaluate the incidence, risk factors, and prognosis of bloodstream infections (BSIs) during extracorporeal membrane oxygenation (ECMO) treatment in a Chinese population.
Patients receiving ECMO treatment from January 2013 to August 2019 were retrospectively studied. The incidence of BSIs was calculated. The clinical characteristics between patients with a BSI (BSI group) and without a BSI (non-BSI group).
Among 69 included patients, 19 (27.5%) developed at least one BSI. Gram-negative bacteria (73.7%) were mainly responsible for the BSIs, with (6/19, 31.5%) ranking as the top related pathogen. The BSI group had a greater proportion of methicillin-resistant (MRSA) prophylactic regimens (52.6% vs. 26.0%, P = 0.036), a higher pre-ECMO Sequential Organ Failure Assessment (SOFA) score (11 vs. 8, P = 0.008), more applications of continuous renal replacement therapy (CRRT) during ECMO (63.1% vs. 36.1%, P = 0.042). Longer ECMO support duration, period of ventilator use before ECMO weaning and hospital stay were observed in the BSI group. The SOFA score (OR: 1.174; 95% CI: 1.039-1.326; P = 0.010) was an independent risk factor for BSIs.
BSIs during ECMO therapy frequently involve Gram-negative bacteria. Stringent care and monitoring should be provided for patients with high SOFA scores.
我们旨在评估中国人群体外膜肺氧合(ECMO)治疗期间血流感染(BSIs)的发生率、危险因素及预后。
回顾性研究2013年1月至2019年8月接受ECMO治疗的患者。计算BSIs的发生率。比较发生BSIs的患者(BSI组)和未发生BSIs的患者(非BSI组)的临床特征。
在纳入的69例患者中,19例(27.5%)发生了至少一次BSIs。革兰氏阴性菌(73.7%)是BSIs的主要致病菌,其中[具体细菌名称未给出](6/19,31.5%)为最主要相关病原体。BSI组耐甲氧西林[具体细菌名称未给出](MRSA)预防性治疗方案的比例更高(52.6%对26.0%,P = 0.036),ECMO前序贯器官衰竭评估(SOFA)评分更高(11对8,P = 0.008),ECMO期间连续肾脏替代治疗(CRRT)的应用更多(63.1%对36.1%,P = 0.042)。BSI组的ECMO支持时间更长,ECMO撤机前呼吸机使用时间和住院时间更长。SOFA评分(OR:1.174;95%CI:1.039 - 1.326;P = 0.010)是BSIs的独立危险因素。
ECMO治疗期间的BSIs常涉及革兰氏阴性菌。对于SOFA评分高的患者应给予严格的护理和监测。